Mycamine (Micafungin Sodium)

Micafungin Sodium, the active ingredient in Mycamine, is an echinocandin presented as an intravenous solution for intravenous use. It treats invasive candidiasis, esophageal candidiasis and is used for prophylaxis of Candida infections in hematopoietic stem cell transplantation. GNH USA supplies Mycamine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Mycamine (micafungin sodium) is used to treat fungal infections that involve the Candida species.

- Invasive candidiasis: effective in treating bloodstream and intra‑abdominal Candida infections. - Esophageal candidiasis: clears infection of the esophageal mucosa caused by Candida. - Prophylaxis in hematopoietic stem cell transplantation: prevents Candida infections in patients undergoing transplant procedures.

Micafungin sodium may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fever: transient elevation of body temperature. - Nausea: mild to moderate feeling of sickness. - Elevated liver enzymes: increase in ALT/AST levels. - Headache: mild headache.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury or failure. - Severe hypersensitivity reactions: anaphylaxis, rash, angioedema. - Infusion‑related reactions: hypotension, bronchospasm. - Renal impairment: acute kidney injury.

Before initiating therapy, clinicians should assess organ function and review concomitant medications. - Renal function: monitor serum creatinine in patients with pre‑existing kidney disease. - Hepatic function: assess liver enzymes before and during therapy. - Drug interactions: review concomitant medications that affect CYP enzymes. - Pregnancy and lactation: use only if potential benefit justifies risk; data limited. - Pediatric use: safety and efficacy not established in children under 1 month. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin may interact with several agents that alter its plasma concentration or increase toxicity risk.

Major Interactions (Avoid): - Cyclosporine: co‑administration may increase micafungin exposure, raising toxicity risk. - Rifampin: strong enzyme inducer may reduce micafungin levels, decreasing efficacy.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): may alter micafungin metabolism; monitor liver function. - Warfarin: potential for altered anticoagulant effect; monitor INR. - Immunosuppressants (e.g., tacrolimus): may require dose adjustment; monitor drug levels.